A growing number of companies are testing muscle-building agents to counter the side effects of dramatic weight loss and potentially to preserve lean muscle into old age.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 March 2024
Since the publication of this article, BioAge pivoted from launching a phase 2 trial testing azelaprag for muscle loss. Text in the print, HTML and PDF versions of the article has been removed to reflect this.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arnold, C. After obesity drugs’ success, companies rush to preserve skeletal muscle. Nat Biotechnol 42, 351–353 (2024). https://doi.org/10.1038/s41587-024-02176-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02176-5
